Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.96 |
| ▸ | GAA | P10253 | 1/20 | 0.96 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.96 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.96 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.45 |
| ▸ | CA12 | O43570 | 4/20 | 0.44 |
| ▸ | CA1 | P00915 | 4/20 | 0.44 |
| ▸ | CA2 | P00918 | 4/20 | 0.44 |
| ▸ | CA7 | P43166 | 4/20 | 0.44 |
| ▸ | CA9 | Q16790 | 4/20 | 0.44 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.44 |
| ▸ | CA4 | P22748 | 2/20 | 0.44 |
| ▸ | CA6 | P23280 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | HMGB1 | P09429 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.44 |
| ▸ | IDE | P14735 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL438546 | 0.98 | ALDH1A1 (1.00) | ALDH1A1GAAKMT2ATDP1ALOX15 | |
| SCHEMBL29636490 | 0.98 | ALDH1A1 (1.00) | ALDH1A1GAAKMT2ATDP1ALOX15 | |
| Phenol SCHEMBL1068767 | 0.96 | ALDH1A1 (0.96) | ALDH1A1GAAKMT2ATDP1ALOX15 | |
| SCHEMBL16018458 | 0.90 | ALDH1A1 (0.84) | ALDH1A1GAAKMT2ATDP1ALOX15 | |
| SCHEMBL8945914 | 0.87 | ALDH1A1 (0.79) | ALDH1A1GAAKMT2ATDP1ALOX15 | |
| SCHEMBL18568766 | 0.82 | ALDH1A1 (0.72) | ALDH1A1GAAKMT2ATDP1ALOX15 | |
| Potassium Ion SCHEMBL1507637 | 0.81 | ALDH1A1 (0.70) | ALDH1A1GAAKMT2ATDP1CA1 | |
| SCHEMBL900830 | 0.80 | ALDH1A1 (0.68) | ALDH1A1GAAKMT2ATDP1ALOX15 | |
| SCHEMBL19474859 | 0.80 | KMT2A (0.69) | ALDH1A1GAAKMT2ATDP1KDM4E | |
| SCHEMBL13172304 | 0.80 | ALDH1A1 (0.69) | ALDH1A1GAAKMT2ATDP1CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2305246-B1 | Tumor necrosis factor inhibitors | UNIV PENNSYLVANIA (US) | 2015-08-26 | — | — | EP | disclosed |
| US-9096607-B2 | Tumor necrosis factor inhibitors | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2015-08-04 | — | — | US | disclosed |
| US-20140256803-A1 | TUMOR NECROSIS FACTOR INHIBITORS | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2014-09-11 | — | — | US | disclosed |
| US-8765810-B2 | Tumor necrosis factor inhibitors | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2014-07-01 | — | — | US | disclosed |
| US-20130072562-A1 | TUMOR NECROSIS FACTOR INHIBITORS | CEPHALON, INC. (US) | 2013-03-21 | — | — | US | disclosed |
| US-8318699-B2 | Tumor necrosis factor inhibitors | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2012-11-27 | — | — | US | disclosed |
| EP-2305246-A1 | Tumor necrosis factor inhibitors | Ception Therapeutics, Inc. (US) | 2011-04-06 | — | — | EP | disclosed |
| EP-2298295-A1 | Tumor necrosis factor inhibitors | Ception Therapeutics, Inc. (US) | 2011-03-23 | — | — | EP | disclosed |
| US-20090221527-A1 | TUMOR NECROSIS FACTOR INHIBITORS | CEPTION THERAPEUTICS, INC. (US) | 2009-09-03 | — | — | US | disclosed |
| EP-1845970-A4 | TUMOR NECROSIS FACTOR INHIBITORS | CEPTION THERAPEUTICS INC (US) | 2009-02-18 | — | — | EP | disclosed |
| EP-1845970-A2 | TUMOR NECROSIS FACTOR INHIBITORS | Ception Therapeutics, Inc. (US) | 2007-10-24 | — | — | EP | disclosed |
| WO-2006083970-A2 | TUMOR NECROSIS FACTOR INHIBITORS | CEPTION THERAPEUTICS, INC. (US) | 2006-08-10 | — | — | WO | disclosed |
| WO-2006083869-A2 | TUMOR NECROSIS FACTOR INHIBITORS | CEPTION THERAPEUTICS, INC. (US) | 2006-08-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090221527-A1 | TUMOR NECROSIS FACTOR INHIBITORS | TNFRSF1A, TNF, TNFRSF9 | ALDH1A1 3912/4885GAA 1674/4885KMT2A 4709/4885 |
| US-20140256803-A1 | TUMOR NECROSIS FACTOR INHIBITORS | TNFRSF1A, TNF, TNFRSF9 | ALDH1A1 3912/4885GAA 1674/4885KMT2A 4709/4885 |
| US-20130072562-A1 | TUMOR NECROSIS FACTOR INHIBITORS | TNFRSF1A, TNF, TNFRSF9 | ALDH1A1 3912/4885GAA 1674/4885KMT2A 4709/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.